End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,895 KRW | -0.17% | -1.36% | -17.05% |
May. 30 | JW (Cayman) Therapeutics Presents Trial Data from SLE Drug at Rheumatology Congress | MT |
May. 14 | JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | 865B 633M | Sales 2023 | 928B 679M | Capitalization | 252B 185M |
---|---|---|---|---|---|
Net income 2022 | 22.15B 16.22M | Net income 2023 | 19.03B 13.93M | EV / Sales 2022 | 0.69 x |
Net Debt 2022 | 389B 285M | Net Debt 2023 | 400B 293M | EV / Sales 2023 | 0.7 x |
P/E ratio 2022 |
9.25
x | P/E ratio 2023 |
13.2
x | Employees | 141 |
Yield 2022 |
3.36% | Yield 2023 |
2.95% | Free-Float | 46% |
1 day | -0.17% | ||
1 week | -1.36% | ||
Current month | -1.03% | ||
1 month | -3.66% | ||
3 months | -12.54% | ||
6 months | -9.14% | ||
Current year | -17.05% |
Managers | Title | Age | Since |
---|---|---|---|
Sung-Kweon Han
CEO | Chief Executive Officer | 66 | - |
Kyung-Ha Lee
CEO | Chief Executive Officer | 60 | - |
Ji-Woo Choi
DFI | Director of Finance/CFO | 58 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Kyung-Ha Lee
CEO | Chief Executive Officer | 60 | - |
Jong-Ho Lee
BRD | Director/Board Member | 91 | - |
Sung-Kweon Han
CEO | Chief Executive Officer | 66 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 2,895 | -0.17% | 43,863 |
24-06-04 | 2,900 | -1.02% | 41,847 |
24-06-03 | 2,930 | +0.17% | 16,809 |
24-05-31 | 2,925 | -0.34% | 16,133 |
24-05-30 | 2,935 | +0.17% | 48,276 |
End-of-day quote Korea S.E., June 04, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-17.05% | 153M | |
+19.39% | 42.33B | |
+21.25% | 22.47B | |
+16.93% | 15.25B | |
+19.83% | 14.29B | |
+53.22% | 12.6B | |
-0.05% | 6.79B | |
-11.11% | 6.71B | |
-8.87% | 5.73B | |
+14.27% | 5.47B |
- Stock Market
- Equities
- A096760 Stock